title: Inactivation of a particle beta-glucan by proteins in plasma and serum.
abstract: (1-->3)-beta-D-Glucans remained in the liver and spleen for long time, i.e. more than a month, without major structural changes/because there is no specific metabolic pathway for it in the body. However, biological activities, such as priming activity to LPS, triggered TNF-alpha synthesis, and antitumor activity was reduced more quickly. In this paper, we demonstrated the contribution of protein binding in inactivating beta-glucans. A particle beta-glucan preparation, zymosan, was treated with serum or plasma at 37 degrees C and their various biological activities were compared with zymosan alone. Such biological activities as antitumor activity, TNF-production, IL-6 production, complement activation and vascular permeability were significantly decreased by serum or plasma treatment. These results strongly suggested that the binding of serum or plasma protein(s) to beta-glucans would be a key step in inactivating a particle beta-glucan in the body.
authors.affiliation: Laboratory for Immunopharmacology of Microbial Products, Tokyo University of Pharmacy and Life Science, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Miura
authors.forename: N
authors.initials: N
authors.lastname: Ohno
authors.forename: N N
authors.initials: NN
authors.lastname: Miura
authors.forename: S
authors.initials: S
authors.lastname: Shimada
authors.forename: T
authors.initials: T
authors.lastname: Yadomae
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000097:blood* / Q000378:metabolism / Q000494:pharmacology; D001798:Blood Proteins / Q000378:metabolism*; D002199:Capillary Permeability / Q000187:drug effects; D003165:Complement System Proteins / Q000378:metabolism; D004912:Erythrocytes / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D015850:Interleukin-6 / Q000378:metabolism; D008099:Liver / Q000187:drug effects; D017737:Macrophages, Peritoneal / Q000187:drug effects / Q000378:metabolism; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D009368:Neoplasm Transplantation; D009929:Organ Size / Q000187:drug effects; D011817:Rabbits; D012510:Sarcoma 180 / Q000473:pathology; D013154:Spleen / Q000187:drug effects; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D015054:Zymosan / Q000097:blood* / Q000378:metabolism / Q000494:pharmacology
chemical_list: D000970:Antineoplastic Agents; D001798:Blood Proteins; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D003165:Complement System Proteins; D015054:Zymosan